Cargando…

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Immunotherapy (IO) and radiotherapy (XRT) are two of the most important treatment modalities in metastatic non-small cell lung cancer. There is data to suggest that XRT can enhance the IO’s efficacy. However, little is known regarding how to best combine them. In this retrospective,...

Descripción completa

Detalles Bibliográficos
Autores principales: Onn, Amir, Gottfried, Teodor, Stemmer, Amos, Appel, Sarit, Lawrence, Yaacov R., Urban, Damien, Beller, Tamar, Daher, Sameh, Bar, Jair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200093/
https://www.ncbi.nlm.nih.gov/pubmed/34199805
http://dx.doi.org/10.3390/cancers13112800
_version_ 1783707530276372480
author Onn, Amir
Gottfried, Teodor
Stemmer, Amos
Appel, Sarit
Lawrence, Yaacov R.
Urban, Damien
Beller, Tamar
Daher, Sameh
Bar, Jair
author_facet Onn, Amir
Gottfried, Teodor
Stemmer, Amos
Appel, Sarit
Lawrence, Yaacov R.
Urban, Damien
Beller, Tamar
Daher, Sameh
Bar, Jair
author_sort Onn, Amir
collection PubMed
description SIMPLE SUMMARY: Immunotherapy (IO) and radiotherapy (XRT) are two of the most important treatment modalities in metastatic non-small cell lung cancer. There is data to suggest that XRT can enhance the IO’s efficacy. However, little is known regarding how to best combine them. In this retrospective, single-center study, we analyze data of 453 patients who have received various combinations of XRT and IO, or IO alone, to assess the treatment parameters that correlate with longer overall survival (OS). XRT doses between 30 and 40 Gy correlated with longer overall survival, while XRT doses below 10 Gy, fractions of 4.1 to 8 Gy and XRT to the bone correlated with worse overall survival. These results require validation with prospective studies. ABSTRACT: Background: Immunotherapy (IO) provides a significant benefit for a subgroup of non-small cell lung cancer (NSCLC) patients. Radiotherapy (XRT) might enhance the efficacy of IO. We evaluated the impact of the specifics of XRT treatments on the OS of IO-treated NSCLC patients. Methods: Metastatic NSCLC patients treated with IO were retrospectively identified. Parameters included demographics, tumor characteristics, IO and XRT details. Correlation between the parameters and OS was tested with Cox regression. Results: 453 patients were included. No XRT was given to 167 (36.9%) patients, whereas XRT prior and after IO had 182 (40.2%) and 104 (22.9%) patients, respectively. XRT total doses between 30 and 40 Gy had better overall survival (OS) compared to non-irradiated patients (hazard ratio (HR) 0.5, 95% CI 0.25–1.0, p = 0.049). Worse outcome was seen with total doses ≤ 10 Gy (HR 1.67, 95% 1.13–2.5, p = 0.01), XRT fractions of 4.1–8 Gy (HR 1.48, 95% CI 1.05–2.1, p = 0.027) and XRT to the bone (HR 1.36, 95% CI 1.01–1.8, p = 0.04). Several clinical parameters correlated with OS in the univariate analysis of the IO-treated patients. While, in the multivariate analysis, only ECOG-PS, treatment line, type of IO, albumin and NLR remained statistically significant. Conclusion: Specific doses, fractions and sites of XRT correlated with the OS of IO-treated NSCLC patients in the univariate analysis, although not in the multivariate analysis.
format Online
Article
Text
id pubmed-8200093
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82000932021-06-14 Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer Onn, Amir Gottfried, Teodor Stemmer, Amos Appel, Sarit Lawrence, Yaacov R. Urban, Damien Beller, Tamar Daher, Sameh Bar, Jair Cancers (Basel) Article SIMPLE SUMMARY: Immunotherapy (IO) and radiotherapy (XRT) are two of the most important treatment modalities in metastatic non-small cell lung cancer. There is data to suggest that XRT can enhance the IO’s efficacy. However, little is known regarding how to best combine them. In this retrospective, single-center study, we analyze data of 453 patients who have received various combinations of XRT and IO, or IO alone, to assess the treatment parameters that correlate with longer overall survival (OS). XRT doses between 30 and 40 Gy correlated with longer overall survival, while XRT doses below 10 Gy, fractions of 4.1 to 8 Gy and XRT to the bone correlated with worse overall survival. These results require validation with prospective studies. ABSTRACT: Background: Immunotherapy (IO) provides a significant benefit for a subgroup of non-small cell lung cancer (NSCLC) patients. Radiotherapy (XRT) might enhance the efficacy of IO. We evaluated the impact of the specifics of XRT treatments on the OS of IO-treated NSCLC patients. Methods: Metastatic NSCLC patients treated with IO were retrospectively identified. Parameters included demographics, tumor characteristics, IO and XRT details. Correlation between the parameters and OS was tested with Cox regression. Results: 453 patients were included. No XRT was given to 167 (36.9%) patients, whereas XRT prior and after IO had 182 (40.2%) and 104 (22.9%) patients, respectively. XRT total doses between 30 and 40 Gy had better overall survival (OS) compared to non-irradiated patients (hazard ratio (HR) 0.5, 95% CI 0.25–1.0, p = 0.049). Worse outcome was seen with total doses ≤ 10 Gy (HR 1.67, 95% 1.13–2.5, p = 0.01), XRT fractions of 4.1–8 Gy (HR 1.48, 95% CI 1.05–2.1, p = 0.027) and XRT to the bone (HR 1.36, 95% CI 1.01–1.8, p = 0.04). Several clinical parameters correlated with OS in the univariate analysis of the IO-treated patients. While, in the multivariate analysis, only ECOG-PS, treatment line, type of IO, albumin and NLR remained statistically significant. Conclusion: Specific doses, fractions and sites of XRT correlated with the OS of IO-treated NSCLC patients in the univariate analysis, although not in the multivariate analysis. MDPI 2021-06-04 /pmc/articles/PMC8200093/ /pubmed/34199805 http://dx.doi.org/10.3390/cancers13112800 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Onn, Amir
Gottfried, Teodor
Stemmer, Amos
Appel, Sarit
Lawrence, Yaacov R.
Urban, Damien
Beller, Tamar
Daher, Sameh
Bar, Jair
Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
title Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
title_full Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
title_fullStr Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
title_full_unstemmed Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
title_short Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
title_sort real-world analysis of the impact of radiotherapy on immunotherapy efficacy in non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200093/
https://www.ncbi.nlm.nih.gov/pubmed/34199805
http://dx.doi.org/10.3390/cancers13112800
work_keys_str_mv AT onnamir realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT gottfriedteodor realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT stemmeramos realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT appelsarit realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT lawrenceyaacovr realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT urbandamien realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT bellertamar realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT dahersameh realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer
AT barjair realworldanalysisoftheimpactofradiotherapyonimmunotherapyefficacyinnonsmallcelllungcancer